June 8, 2026

•

XX

min read

The CRISPR and gene-editing patent landscape is one of the largest and most contested in biotechnology, and freedom-to-operate in this field is correspondingly difficult. A landscape analysis maintained by a national patent office counted roughly 23,700 CRISPR patent families as of the end of 2024, an increase of more than 6,500 families in a single year, and it identified four competing groups holding foundational claims.¹ Freedom-to-operate determines whether making, using, or selling a product would infringe another party's active patent claims. In gene editing, the foundational rights are split across multiple owners and jurisdictions, so a developer frequently cannot clear a product by licensing from a single source and must instead assemble rights from several, with the required set depending on the application and the country.¹,²

The fragmentation traces to an unresolved priority dispute over who first applied CRISPR-Cas9 to eukaryotic cells. The two most prominent groups are the University of California, Berkeley, the University of Vienna, and Emmanuelle Charpentier on one side, and the Broad Institute of MIT and Harvard on the other, with ToolGen and Sigma-Aldrich also holding foundational filings. The dispute has run through patent offices and courts for over a decade, and it remains live: in May 2025 the US Court of Appeals for the Federal Circuit vacated and remanded a decision that had awarded priority for eukaryotic CRISPR-Cas9 to the Broad Institute, reviving the Berkeley-led group's challenge.³,⁶ In Europe, the Berkeley-led group withdrew two foundational patents in late 2024 following an unfavorable preliminary opinion, then pursued divisional claims, while ToolGen secured European positions during 2025, illustrating how the landscape continues to shift among the competing groups.²,⁷ The academic literature has tracked this contested landscape since the technology's early years, documenting both its fragmentation and the licensing complexity it creates, and has examined proposed responses such as CRISPR patent pools.⁴,⁵,⁸

The practical consequence is that gene-editing FTO is a licensing-and-landscape problem, not a single clearance. The required rights differ by use, human therapeutics, agricultural and plant applications, research tools, and diagnostics can each implicate different foundational and improvement patents, and they differ by jurisdiction, because the same dispute has resolved differently in the United States, Europe, and Asia. The uncertainty is compounded by timing: some of the earliest, broadest patents may expire before the disputes are fully resolved, which shifts value toward the dense layer of improvement patents on delivery, specificity, and newer editing systems.² Because applications publish about eighteen months after filing, the most recent activity is under-represented, so the landscape is even larger and more active than granted-patent counts suggest.

Why CRISPR freedom-to-operate is hard

Fragmented foundational rights. Foundational claims are split across at least four groups, so clearing a product often requires multiple licenses rather than one.¹

Unresolved disputes. The priority dispute over eukaryotic CRISPR-Cas9 remains active, with a US Federal Circuit ruling in May 2025 reviving the Berkeley-led challenge, so ownership is not yet settled.³

Jurisdictional divergence. The same dispute has resolved differently across the United States, Europe, and Asia, so FTO must be assessed market-by-market.²

Application-specific rights. Human therapeutics, agriculture, research tools, and diagnostics implicate different patents, so the required license set depends on the intended use.¹

A dense improvement layer. Beyond the foundational patents, a large and growing layer of improvement patents covers delivery, specificity, base and prime editing, and newer nucleases, which is where much current FTO risk and white space now sit, including in application areas such as agricultural gene editing.⁹

How AI-powered landscape and FTO analysis helps

Navigating a landscape of more than twenty thousand families across multiple owners, applications, and jurisdictions is beyond manual search. AI-powered analysis addresses this with semantic search that retrieves relevant claims regardless of terminology, attribution that resolves owners to canonical entities so the fragmentation is visible, and continuous monitoring that tracks a fast-shifting landscape as disputes resolve and improvement patents publish. Because gene-editing advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the improvement layer is extending.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for complex, fragmented fields such as gene editing across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by technology and application and normalizes owners to canonical entities, so a team can see how foundational and improvement rights are distributed across the four groups and the many later filers rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where the improvement layer emerges first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim analysis, and Agentic Monitoring tracks the landscape over time and flags new filings and dispute developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

How large is the CRISPR patent landscape?

The CRISPR patent landscape is very large. A national patent office landscape analysis counted roughly 23,700 CRISPR patent families as of the end of 2024, up more than 6,500 in a single year. Because applications publish about eighteen months after filing, the most recent activity is under-represented, so the true landscape is even larger.

Why is freedom-to-operate hard for CRISPR?

Freedom-to-operate is hard for CRISPR because foundational rights are split across at least four competing groups and the key priority dispute remains unresolved, so a developer often cannot clear a product with a single license. The required rights also differ by application and jurisdiction. Assembling the correct set of licenses is the central FTO challenge.

What is the Broad versus UC Berkeley CRISPR dispute?

The Broad versus UC Berkeley dispute concerns who first applied CRISPR-Cas9 to eukaryotic cells, contested between the Berkeley-led group and the Broad Institute, with ToolGen and Sigma-Aldrich also holding foundational filings. In May 2025, the US Court of Appeals for the Federal Circuit vacated and remanded a decision that had favored the Broad Institute, reviving the Berkeley-led challenge. The dispute remains unresolved.

Does CRISPR freedom-to-operate differ by country?

Yes, CRISPR freedom-to-operate differs by country, because the same foundational dispute has resolved differently in the United States, Europe, and Asia. A party may hold stronger rights in one jurisdiction than another. FTO must therefore be assessed market-by-market rather than globally.

Why might a CRISPR product need multiple licenses?

A CRISPR product may need multiple licenses because foundational rights are fragmented across several owners, and improvement patents on delivery, specificity, and newer editing systems add further layers. The required set depends on the application and jurisdiction. This is why gene-editing FTO is a licensing-and-landscape problem rather than a single clearance.

How does the improvement-patent layer affect CRISPR FTO?

The improvement-patent layer affects CRISPR FTO because, beyond the foundational patents, a large and growing set of patents covers delivery, specificity, base and prime editing, and newer nucleases. As the earliest broad patents approach expiry, value shifts toward this layer, which is where much current FTO risk and white space sit. Mapping it requires reading both patents and scientific literature.

How does scientific literature help CRISPR landscape analysis?

Scientific literature helps CRISPR landscape analysis because gene-editing advances appear in research before they are patented, so the literature gives the earliest signal of where the improvement layer is extending. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams need CRISPR patent landscape and FTO analysis?

CRISPR patent landscape and FTO analysis is needed by R&D, IP, and business-development teams in therapeutics, agriculture, industrial biotechnology, and diagnostics, along with investors assessing gene-editing assets. The fragmentation makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

How current does a CRISPR landscape need to be?

A CRISPR landscape needs to be continuously current, because the disputes are still resolving, new improvement patents publish constantly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track the landscape and flag new filings and developments as they publish.

Endnotes

Swiss Federal Institute of Intellectual Property (2025). CRISPR Technology: Patent & Licence Landscapes. https://www.ige.ch/
Gowling WLG (2025). Fragmented and shifting CRISPR patent landscape: global proceedings and the patent pool solution. https://gowlingwlg.com/en/insights-resources/articles/2025/crispr-patent-landscape
US Court of Appeals for the Federal Circuit (2025). Regents of the University of California v. Broad Institute, Inc., decided May 12, 2025. https://www.cafc.uscourts.gov/
Egelie, K. J., Graff, G. D., Strand, S. P. & Johansen, B. (2016). The emerging patent landscape of CRISPR-Cas gene editing technology. Nature Biotechnology. https://doi.org/10.1038/nbt.3692
Contreras, J. L. & Sherkow, J. S. (2017). CRISPR, surrogate licensing, and scientific discovery. Science. https://doi.org/10.1126/science.aal4222
Sherkow, J. S. (2025). A "Bare Hope of a Result": The Second CRISPR Patent Appeal. The CRISPR Journal (analysis of the May 12, 2025 US Federal Circuit decision).
Beck Greener (2025). Update on the CRISPR-Cas9 IP saga at the EPO: blows for both the Broad and CVC camps, but ToolGen ends 2025 with success. https://www.beckgreener.com/
Stasi, A. & Pereira Rodrigues, I. (2019). Dealing with Patent Fragmentation in Genetics: Can Patent Pools Facilitate the Development of CRISPR Gene-Editing Technology? PubMed.
Muhammad Adamu, U. et al. (2026). CRISPR in Wheat: Patents, Breeding Advances, and Emerging Challenges. Trends in Intellectual Property Research.

‍

CRISPR and Gene-Editing Patent Landscape and Freedom-to-Operate in 2026

Writen By:

Cypris Research Team

Table of contents

Register here

Subscribe to receive the latest blog posts to your inbox every week.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

The CRISPR and gene-editing patent landscape is one of the largest and most contested in biotechnology, and freedom-to-operate in this field is correspondingly difficult. A landscape analysis maintained by a national patent office counted roughly 23,700 CRISPR patent families as of the end of 2024, an increase of more than 6,500 families in a single year, and it identified four competing groups holding foundational claims.¹ Freedom-to-operate determines whether making, using, or selling a product would infringe another party's active patent claims. In gene editing, the foundational rights are split across multiple owners and jurisdictions, so a developer frequently cannot clear a product by licensing from a single source and must instead assemble rights from several, with the required set depending on the application and the country.¹,²

The fragmentation traces to an unresolved priority dispute over who first applied CRISPR-Cas9 to eukaryotic cells. The two most prominent groups are the University of California, Berkeley, the University of Vienna, and Emmanuelle Charpentier on one side, and the Broad Institute of MIT and Harvard on the other, with ToolGen and Sigma-Aldrich also holding foundational filings. The dispute has run through patent offices and courts for over a decade, and it remains live: in May 2025 the US Court of Appeals for the Federal Circuit vacated and remanded a decision that had awarded priority for eukaryotic CRISPR-Cas9 to the Broad Institute, reviving the Berkeley-led group's challenge.³,⁶ In Europe, the Berkeley-led group withdrew two foundational patents in late 2024 following an unfavorable preliminary opinion, then pursued divisional claims, while ToolGen secured European positions during 2025, illustrating how the landscape continues to shift among the competing groups.²,⁷ The academic literature has tracked this contested landscape since the technology's early years, documenting both its fragmentation and the licensing complexity it creates, and has examined proposed responses such as CRISPR patent pools.⁴,⁵,⁸

The practical consequence is that gene-editing FTO is a licensing-and-landscape problem, not a single clearance. The required rights differ by use, human therapeutics, agricultural and plant applications, research tools, and diagnostics can each implicate different foundational and improvement patents, and they differ by jurisdiction, because the same dispute has resolved differently in the United States, Europe, and Asia. The uncertainty is compounded by timing: some of the earliest, broadest patents may expire before the disputes are fully resolved, which shifts value toward the dense layer of improvement patents on delivery, specificity, and newer editing systems.² Because applications publish about eighteen months after filing, the most recent activity is under-represented, so the landscape is even larger and more active than granted-patent counts suggest.

Why CRISPR freedom-to-operate is hard

Fragmented foundational rights. Foundational claims are split across at least four groups, so clearing a product often requires multiple licenses rather than one.¹

Unresolved disputes. The priority dispute over eukaryotic CRISPR-Cas9 remains active, with a US Federal Circuit ruling in May 2025 reviving the Berkeley-led challenge, so ownership is not yet settled.³

Jurisdictional divergence. The same dispute has resolved differently across the United States, Europe, and Asia, so FTO must be assessed market-by-market.²

Application-specific rights. Human therapeutics, agriculture, research tools, and diagnostics implicate different patents, so the required license set depends on the intended use.¹

A dense improvement layer. Beyond the foundational patents, a large and growing layer of improvement patents covers delivery, specificity, base and prime editing, and newer nucleases, which is where much current FTO risk and white space now sit, including in application areas such as agricultural gene editing.⁹

How AI-powered landscape and FTO analysis helps

Navigating a landscape of more than twenty thousand families across multiple owners, applications, and jurisdictions is beyond manual search. AI-powered analysis addresses this with semantic search that retrieves relevant claims regardless of terminology, attribution that resolves owners to canonical entities so the fragmentation is visible, and continuous monitoring that tracks a fast-shifting landscape as disputes resolve and improvement patents publish. Because gene-editing advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the improvement layer is extending.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for complex, fragmented fields such as gene editing across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by technology and application and normalizes owners to canonical entities, so a team can see how foundational and improvement rights are distributed across the four groups and the many later filers rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where the improvement layer emerges first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim analysis, and Agentic Monitoring tracks the landscape over time and flags new filings and dispute developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

How large is the CRISPR patent landscape?

The CRISPR patent landscape is very large. A national patent office landscape analysis counted roughly 23,700 CRISPR patent families as of the end of 2024, up more than 6,500 in a single year. Because applications publish about eighteen months after filing, the most recent activity is under-represented, so the true landscape is even larger.

Why is freedom-to-operate hard for CRISPR?

Freedom-to-operate is hard for CRISPR because foundational rights are split across at least four competing groups and the key priority dispute remains unresolved, so a developer often cannot clear a product with a single license. The required rights also differ by application and jurisdiction. Assembling the correct set of licenses is the central FTO challenge.

What is the Broad versus UC Berkeley CRISPR dispute?

The Broad versus UC Berkeley dispute concerns who first applied CRISPR-Cas9 to eukaryotic cells, contested between the Berkeley-led group and the Broad Institute, with ToolGen and Sigma-Aldrich also holding foundational filings. In May 2025, the US Court of Appeals for the Federal Circuit vacated and remanded a decision that had favored the Broad Institute, reviving the Berkeley-led challenge. The dispute remains unresolved.

Does CRISPR freedom-to-operate differ by country?

Yes, CRISPR freedom-to-operate differs by country, because the same foundational dispute has resolved differently in the United States, Europe, and Asia. A party may hold stronger rights in one jurisdiction than another. FTO must therefore be assessed market-by-market rather than globally.

Why might a CRISPR product need multiple licenses?

A CRISPR product may need multiple licenses because foundational rights are fragmented across several owners, and improvement patents on delivery, specificity, and newer editing systems add further layers. The required set depends on the application and jurisdiction. This is why gene-editing FTO is a licensing-and-landscape problem rather than a single clearance.

How does the improvement-patent layer affect CRISPR FTO?

The improvement-patent layer affects CRISPR FTO because, beyond the foundational patents, a large and growing set of patents covers delivery, specificity, base and prime editing, and newer nucleases. As the earliest broad patents approach expiry, value shifts toward this layer, which is where much current FTO risk and white space sit. Mapping it requires reading both patents and scientific literature.

How does scientific literature help CRISPR landscape analysis?

Scientific literature helps CRISPR landscape analysis because gene-editing advances appear in research before they are patented, so the literature gives the earliest signal of where the improvement layer is extending. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams need CRISPR patent landscape and FTO analysis?

CRISPR patent landscape and FTO analysis is needed by R&D, IP, and business-development teams in therapeutics, agriculture, industrial biotechnology, and diagnostics, along with investors assessing gene-editing assets. The fragmentation makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

How current does a CRISPR landscape need to be?

A CRISPR landscape needs to be continuously current, because the disputes are still resolving, new improvement patents publish constantly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track the landscape and flag new filings and developments as they publish.

Endnotes

Swiss Federal Institute of Intellectual Property (2025). CRISPR Technology: Patent & Licence Landscapes. https://www.ige.ch/
Gowling WLG (2025). Fragmented and shifting CRISPR patent landscape: global proceedings and the patent pool solution. https://gowlingwlg.com/en/insights-resources/articles/2025/crispr-patent-landscape
US Court of Appeals for the Federal Circuit (2025). Regents of the University of California v. Broad Institute, Inc., decided May 12, 2025. https://www.cafc.uscourts.gov/
Egelie, K. J., Graff, G. D., Strand, S. P. & Johansen, B. (2016). The emerging patent landscape of CRISPR-Cas gene editing technology. Nature Biotechnology. https://doi.org/10.1038/nbt.3692
Contreras, J. L. & Sherkow, J. S. (2017). CRISPR, surrogate licensing, and scientific discovery. Science. https://doi.org/10.1126/science.aal4222
Sherkow, J. S. (2025). A "Bare Hope of a Result": The Second CRISPR Patent Appeal. The CRISPR Journal (analysis of the May 12, 2025 US Federal Circuit decision).
Beck Greener (2025). Update on the CRISPR-Cas9 IP saga at the EPO: blows for both the Broad and CVC camps, but ToolGen ends 2025 with success. https://www.beckgreener.com/
Stasi, A. & Pereira Rodrigues, I. (2019). Dealing with Patent Fragmentation in Genetics: Can Patent Pools Facilitate the Development of CRISPR Gene-Editing Technology? PubMed.
Muhammad Adamu, U. et al. (2026). CRISPR in Wheat: Patents, Breeding Advances, and Emerging Challenges. Trends in Intellectual Property Research.

‍

Keep Reading

July 20, 2026

•

XX

min read

Claude is a formidable reasoner, but unaided it answers patent and scientific questions from training data — and training data is not the patent record. The constraint is not intelligence; it is access. Without a live connection, Claude can overlook recent filings, misstate priority dates, or fabricate a patent number with complete confidence. The Model Context Protocol (MCP) closes that gap. It connects Claude to an authoritative source, so the model retrieves real records and reasons over them rather than reconstructing them from memory.

MCP is the open standard Anthropic introduced in late 2024, now supported across every major AI platform. Within the Claude ecosystem, Claude Desktop, Claude Code, and Claude Science each act as an MCP host that can call external connectors. This article sets out how those connectors work, how to connect patent and scientific data to Claude, and why the connector you choose determines the quality of the answer far more than the act of connecting.

How MCP works in Claude

An MCP host — Claude Desktop, Claude Code, or Claude Science — runs a client that discovers available connectors and translates a request into structured tool calls. The connector authenticates to the data source, formats the query, and returns structured records; Claude then reasons over them in the conversation. Connectors are configured in Claude's settings, not built from scratch, and MCP's security model rests on OAuth-scoped tokens and read-only access — the controls that make connecting external data defensible in an enterprise setting.

The effect is consequential. A plain-language question in Claude becomes a genuine query against a patent or scientific source, and the returned records are available for Claude to analyze, summarize, and cite with provenance.

What you can connect

A growing set of open-source MCP connectors expose public patent and scientific sources to Claude. Connectors exist for USPTO data through Patent Public Search and the Open Data Portal, for the EPO through the OPS API, and for Google Patents through third-party APIs, alongside academic connectors for arXiv and PubMed. Independent projects such as Patent Connector link Claude directly to official patent-office data across multiple jurisdictions.

These connectors solve access. They let Claude retrieve records from a named authority in natural language, eliminating the copy-paste workflow and the transcription errors a model makes when it reads patent data off a web page.

Access is the easy part

Connecting Claude to a dataset is now trivial. Reasoning over it is not. A point connector hands Claude an undifferentiated stream of records from a single source and delegates all interpretation to the model — and the evidence on context engineering is unambiguous: flooding a model with a large, unscoped set of records degrades accuracy rather than improving it.

Most open-source connectors also cover a single source. A complete R&D question spans the patent record and the scientific literature at once, so answering it through point connectors means running several and reconciling their output by hand. For an isolated lookup that is acceptable; for prior art, freedom-to-operate, or landscape work, it reinstates the very fragmentation MCP was meant to eliminate.

Point connector versus domain-oriented agent

The decisive distinction is between a connector that exposes a dataset and an agent built around a domain. A domain-oriented agent is shaped around a field's data, ontology, and workflows, so retrieval is scoped before it ever reaches Claude's context. Instead of returning everything a keyword matches, it surfaces the high-signal patents and papers that bear on the question. Access alone does not make Claude reason well about patents; the domain layer does.

This matters most in Claude Science, Claude's environment for analytical research. Claude Science reasons powerfully over technical material but carries none of the competitive and landscape context held in the patent and scientific record. A domain-oriented agent connected through MCP supplies precisely that signal, so an agent reasoning about a research problem can also judge whether it aligns with where the field is heading.

Connecting patent data to Claude in practice

Cypris exposes its intelligence layer to Claude through an MCP server, so the competitive and landscape context it maintains connects directly into Claude Desktop, Claude Code, or Claude Science. Rather than handing Claude a broad dataset, it applies a proprietary R&D ontology over a corpus of more than 500 million patents and scientific papers to scope retrieval to what a question actually requires.

Cypris Q, the platform's agentic layer, runs prior art, white space, freedom-to-operate, and regulatory workflows and returns cited output; Agentic Monitoring keeps a position current as new records publish. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

FAQ

Can Claude search patents using MCP?

Claude can search patents using MCP when a patent connector is added through its settings, with Claude Desktop and Claude Code acting as MCP hosts. Claude calls the connector's search and retrieval tools and reasons over the returned records, which lets it work from real filings rather than training data.

How do I connect patent data to Claude?

You connect patent data to Claude by adding an MCP connector in Claude's settings, then letting Claude call that connector's tools during a conversation. The connector authenticates to a patent source and returns structured records, so a plain-language question becomes a real query rather than a recall from memory.

What is Claude Science and how does it use MCP?

Claude Science is Claude's environment for analytical research work, and it supports MCP connectors. Because it is strong at reasoning but does not carry patent and competitive landscape context, connecting a domain-oriented agent through MCP supplies that external signal to its analysis.

What is the difference between Claude Desktop and Claude Code for MCP?

Claude Desktop and Claude Code are both MCP hosts that can call connectors, differing mainly in setting: Claude Desktop is the general assistant environment, while Claude Code is oriented to engineering workflows. Either can connect to a patent or scientific data source through MCP.

Which open-source MCP connectors work with Claude?

Open-source MCP connectors for Claude include ones for USPTO Patent Public Search and the Open Data Portal, the EPO OPS API, Google Patents through third-party APIs, and academic sources such as arXiv and PubMed. Most cover a single source, so spanning patents and literature usually means running several.

Is connecting Claude to a dataset enough for patent research?

Connecting Claude to a dataset solves access but not reasoning, because a raw connector floods the model with records and an overwhelmed model reasons less accurately. Pairing retrieval with a domain ontology, so only high-signal records reach Claude, is what produces reliable analysis.

What is the difference between a point connector and a domain-oriented agent?

A point connector exposes one dataset and leaves interpretation to Claude, while a domain-oriented agent is built around a field's data, ontology, and workflows and scopes retrieval before it reaches the model. The connector improves retrieval; the agent improves the answer.

Can Cypris and Claude be used together?

Cypris and Claude can be used together, because Cypris exposes its intelligence layer through an MCP server and Claude supports MCP connectors, including in Claude Science. The landscape and competitive context Cypris maintains can be connected into Claude so an agent draws on external signal while it reasons.

Are MCP connectors secure for enterprise use with Claude?

MCP's security model relies on OAuth-scoped tokens and read-only access patterns, which is what makes connecting external data to Claude viable for enterprise use. Enterprise deployments should also confirm workspace-level controls and how data is handled with the underlying model provider.

What is the best way to give Claude patent and scientific data?

The best way to give Claude patent and scientific data for R&D work is a domain-oriented agent rather than a raw connector, because stage-gate work spans patents and literature and requires reasoning, not just retrieval. Cypris connects to Claude through an MCP server over a corpus of more than 500 million patents and scientific papers organized by a proprietary R&D ontology.

‍

Claude MCP for Patent Research: Connecting Live Patent and Scientific Data

Blogs

July 20, 2026

•

XX

min read

Regulatory intelligence is the discipline of tracking the approvals, submissions, guidance, and standards that decide whether a technology can reach the market. In regulated industries it stands alongside patent and scientific intelligence as a gate on every R&D program. A technology can be genuinely novel, fully patent-clear, and still be blocked, delayed, or reshaped by a single regulatory decision.

The signals are public but scattered across many bodies and formats: approvals and clearances, submission and trial records, guidance documents and rule changes, standards, labeling, and safety actions. Their value is highest early — before a rule change or a competitor's approval is widely understood. This article sets out how AI-powered regulatory intelligence works for R&D teams in 2026, and how it connects to the patent and scientific record.

What regulatory intelligence covers

Regulatory intelligence spans the full regulatory footprint of a technology area: approvals and clearances, submissions and clinical or field trial records, agency guidance and rule changes, technical standards, labeling requirements, and safety actions such as recalls. The relevant bodies differ by sector — drug and device regulators, environmental and chemical agencies, standards organizations — but the task is constant: know what has changed, what is pending, and what it means for a program.

The payoff is lead time and avoided risk. A competitor's submission reveals its direction and timeline. A guidance change can open or foreclose a development path. Catching either early is the difference between steering a program and being overtaken by a decision after the fact.

Why manual regulatory tracking lags

Manual regulatory tracking means monitoring dozens of agency websites and databases separately, then compiling findings by hand. It is slow, and it is partial. Keyword-based tracking misses documents that describe the same technology or requirement in different terms, and single-source monitoring severs the connection between a regulatory signal and the patent or scientific activity around the same technology.

It is also episodic. A periodic regulatory report is stale the moment a new decision publishes, and the window between refreshes is precisely where a missed signal becomes a missed deadline. Rising regulatory activity across sectors only widens that gap.

How AI-powered regulatory intelligence works

AI-powered regulatory intelligence replaces periodic keyword monitoring with continuous, meaning-based retrieval. Semantic search surfaces relevant approvals, submissions, and guidance by concept, so a signal registers even when it uses unfamiliar terminology. An R&D ontology organizes those signals by technology domain, tying each regulatory event to the specific technology and the organizations pursuing it.

Continuous monitoring runs the analysis without waiting for a scheduled review. It interprets each new regulatory signal against a defined domain, separates the material from the routine, and delivers contextualized alerts rather than raw document links. Because agents span sources, regulatory events can be correlated with patents, scientific literature, and corporate activity into a single picture of where a technology and its competitors are moving.

Connecting regulatory signals to patents and science

Regulatory intelligence is most valuable when it is not siloed. A regulatory decision is one input to a stage-gate, alongside prior art, freedom-to-operate, and the competitive landscape. Connecting regulatory signals to the patent and scientific record lets a team see that a competitor's approval aligns with a filing cluster and a research push — a far stronger signal than any one source read alone.

This is the shift AI enables: from monitoring agencies one at a time to interpreting regulatory change in the context of the full technology picture, and from a static report to intelligence that updates the moment decisions publish.

Regulatory intelligence in practice

Cypris is an AI-native R&D intelligence platform whose Agentic Monitoring capability tracks regulatory bodies continuously, alongside patent offices, scientific literature, M&A activity, product launches, grant awards, and corporate news. It interprets these signals through a proprietary R&D ontology over a corpus of more than 500 million patents and scientific papers, so a regulatory event is tied to the technology and the organizations it concerns rather than read in isolation.

Cypris Q, the platform's agentic layer, lets teams move from a regulatory signal into prior art, white space, or freedom-to-operate analysis on the same technology, in one environment, with cited output. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

FAQ

What is regulatory intelligence for R&D?

Regulatory intelligence for R&D is the practice of tracking the approvals, submissions, guidance, and standards that determine whether a technology can reach the market. It sits alongside patent and scientific intelligence as a gate on a program, because a technology can be patent-clear and still be blocked or delayed by a regulatory decision.

How is regulatory intelligence different from patent monitoring?

Regulatory intelligence tracks regulatory signals such as approvals, submissions, and guidance, while patent monitoring tracks filings. Both gate an R&D program, and the fullest picture comes from correlating them, since a competitor's approval often aligns with its patent and research activity.

What signals does regulatory intelligence track?

Regulatory intelligence tracks approvals and clearances, submissions and trial records, agency guidance and rule changes, technical standards, labeling requirements, and safety actions such as recalls. The relevant bodies vary by sector, but the task is to know what has changed, what is pending, and what it means.

Why does regulatory intelligence matter for R&D?

Regulatory intelligence matters for R&D because a regulatory decision can open or close a development path regardless of a technology's novelty or patent position. Catching a guidance change or a competitor's submission early is the difference between adjusting a program and being caught by a decision after the fact.

How does AI improve regulatory intelligence?

AI improves regulatory intelligence by replacing periodic keyword monitoring with continuous semantic retrieval, so relevant approvals, submissions, and guidance are found by concept even when terminology differs. An R&D ontology then organizes the signals by domain and connects them to the technology and organizations involved.

Can regulatory signals be tracked continuously?

Regulatory signals can be tracked continuously with agentic monitoring that interprets new decisions against a defined technology domain and delivers contextualized alerts as they publish. This replaces periodic manual reports, which are stale as soon as a new decision appears.

How does regulatory intelligence connect to patents and science?

Regulatory intelligence connects to patents and science when the same platform correlates a regulatory event with the filings and research around the same technology. This produces a stronger signal than any single source, and it lets a regulatory decision feed directly into prior art or freedom-to-operate review.

Which sectors rely most on regulatory intelligence?

Regulated industries rely most on regulatory intelligence, including pharmaceuticals, medical devices, chemicals, advanced materials, and energy, where approvals and standards gate commercialization. In these sectors a regulatory signal can reshape an R&D program's timeline and direction.

What public sources support regulatory intelligence?

Public sources that support regulatory intelligence include agency databases and registers such as those published by drug, device, environmental, and standards bodies, along with trial registries and official rule-change publications. Unifying and interpreting these fragmented sources is what an AI-powered platform adds.

What is the best platform for regulatory intelligence in R&D?

The best platform for regulatory intelligence in R&D tracks regulatory signals continuously and connects them to the patent and scientific record. Cypris tracks regulatory bodies through Agentic Monitoring alongside patents, literature, and corporate signals, interpreted through a proprietary R&D ontology over a corpus of more than 500 million patents and scientific papers.

‍

Regulatory Intelligence for R&D: Tracking Approvals, Filings, and Rules Across a Technology Area

Blogs

July 20, 2026

•

XX

min read

ChatGPT is the assistant many R&D and IP teams already use, but on its own it answers patent questions from training data. It can miss recent filings, confuse filing and publication dates, or produce a patent number that does not exist. Connecting ChatGPT to a live source through the Model Context Protocol (MCP) fixes this, so it retrieves real records and reasons over them.

MCP is an open standard introduced by Anthropic in late 2024 and now supported across the major AI platforms, ChatGPT among them. This article explains how ChatGPT's connectors and apps work, how to connect patent and scientific data, and why the choice of connector determines whether the output is reliable.

How connectors and apps work in ChatGPT

ChatGPT connects to external data through MCP-based apps. OpenAI renamed connectors to apps in December 2025, and in 2026 moved the app directory into a broader plugin directory, but the underlying mechanism is unchanged: an app is an MCP integration that lets ChatGPT call approved tools and retrieve information from a service. Custom MCP servers are added through Developer Mode, and on workspace plans administrators control whether custom apps are allowed and how they roll out.

Once connected, ChatGPT can call the app's tools during a chat or in deep research, so a plain-language question becomes a structured query against a patent or scientific source. MCP's security model relies on OAuth-scoped tokens and read-only access patterns, which keeps the connection appropriate for enterprise use.

What you can connect

Several open-source MCP servers expose public patent and scientific sources to ChatGPT. There are connectors for USPTO data through Patent Public Search and the Open Data Portal, for the EPO through the OPS API, and for Google Patents through third-party APIs, alongside academic connectors for arXiv and PubMed. Independent projects such as Patent Connector link ChatGPT directly to official patent-office data across several jurisdictions.

These connectors solve access. They let ChatGPT retrieve records from a specific authority in natural language, which removes the manual copy-paste loop and the errors a model makes when it reads patent data off a web page.

Access is the easy part

Connecting ChatGPT to a dataset is now straightforward. Reasoning over it well is the harder problem. A point connector hands ChatGPT a stream of raw records from one source and leaves interpretation to the model, and research on context engineering shows that flooding a model with a large, undifferentiated set of records degrades accuracy rather than improving it.

Most open-source connectors also cover a single source, so a question that spans the patent record and the scientific literature usually means running several apps and reconciling their output by hand. That is acceptable for a quick lookup but not for prior art, freedom-to-operate, or landscape work.

Point connector versus domain-oriented agent

The meaningful distinction is between an app that exposes a dataset and an agent built around a domain. A domain-oriented agent is shaped around a field's data, ontology, and workflows, so retrieval is scoped before it reaches ChatGPT's context. Rather than returning everything a keyword matches, it retrieves the high-signal patents and papers relevant to the question. Access alone does not make ChatGPT reason well about patents; the domain layer does.

For teams on workspace plans, this also simplifies governance. A single domain-oriented app under administrator control is easier to manage and audit than a stack of point connectors, each with its own source, credentials, and maintenance burden.

Connecting patent data to ChatGPT in practice

Cypris exposes its intelligence layer through an MCP server, so its competitive and landscape context can be connected into ChatGPT as an app. Rather than handing ChatGPT a broad dataset, it uses a proprietary R&D ontology over a corpus of more than 500 million patents and scientific papers to scope retrieval to what matters for a question, and returns source-traceable results ChatGPT can cite.

Cypris Q, the platform's agentic layer, runs prior art, white space, freedom-to-operate, and regulatory workflows and returns cited output, and Agentic Monitoring keeps a position current as new records publish. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

FAQ

Can ChatGPT search patents using MCP?

ChatGPT can search patents using MCP when a patent app or connector is added, after which it calls the app's tools to retrieve records during a chat or deep research. This lets ChatGPT work from real filings rather than training data, which removes the hallucination and stale-coverage problems of answering from memory.

How do I connect patent data to ChatGPT?

You connect patent data to ChatGPT by adding an MCP-based app, typically a custom MCP server through Developer Mode, subject to any workspace controls. Once connected, ChatGPT can call the app's tools so a plain-language question becomes a structured query against a patent source.

What are ChatGPT apps and connectors?

ChatGPT apps are MCP integrations that let ChatGPT call approved tools and retrieve information from a service; OpenAI renamed connectors to apps in December 2025 and later organized them in a plugin directory. The mechanism is MCP, so the same standard used by other assistants applies.

What is Developer Mode in ChatGPT?

Developer Mode is the setting that lets you add custom MCP servers to ChatGPT beyond the built-in apps. It is how a team connects a specific patent or scientific data source that is not already offered as a packaged app.

Which open-source MCP connectors work with ChatGPT?

Open-source MCP connectors for ChatGPT include ones for USPTO Patent Public Search and the Open Data Portal, the EPO OPS API, Google Patents through third-party APIs, and academic sources such as arXiv and PubMed. Most cover a single source, so spanning patents and literature usually means running several.

Is connecting ChatGPT to a dataset enough for patent research?

Connecting ChatGPT to a dataset solves access but not reasoning, because a raw connector floods the model with records and an overwhelmed model reasons less accurately. Pairing retrieval with a domain ontology, so only high-signal records reach ChatGPT, is what produces reliable analysis.

How do enterprise controls work for ChatGPT apps?

On workspace plans, administrators control whether custom apps are allowed and how they roll out, which lets an organization govern what data ChatGPT can reach. Combined with MCP's OAuth-scoped, read-only access model, this is what makes connecting external data appropriate for enterprise use.

What is the difference between a point connector and a domain-oriented agent?

A point connector exposes one dataset and leaves interpretation to ChatGPT, while a domain-oriented agent is built around a field's data, ontology, and workflows and scopes retrieval before it reaches the model. The connector improves retrieval; the agent improves the answer, and it is also easier to govern as a single app.

Can Cypris and ChatGPT be used together?

Cypris and ChatGPT can be used together, because Cypris exposes its intelligence layer through an MCP server and ChatGPT connects to MCP servers as apps. The landscape and competitive context Cypris maintains can be connected into ChatGPT so it reasons over scoped, source-traceable records.

What is the best way to give ChatGPT patent and scientific data?

The best way to give ChatGPT patent and scientific data for R&D work is a domain-oriented agent rather than a raw connector, because stage-gate work spans patents and literature and requires reasoning, not just retrieval. Cypris connects to ChatGPT through an MCP server over a corpus of more than 500 million patents and scientific papers organized by a proprietary R&D ontology.

‍

How to Connect Patent and Scientific Data to ChatGPT with MCP

Blogs